Optimal and Ensure Trials - Based Combined Cost-Effectiveness Analysis of Erlotinib Versus Chemotherapy for the First- Line Treatment of Asian Patients with Nonsquamous Non– Small-Cell Lung Cancer

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.08.274
https://www.valueinhealthjournal.com/article/S1098-3015(16)30854-3/fulltext
Section Title : Disease-Specific Studies
Section Order : 2735
First Page : A888
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30854-3&doi=10.1016/j.jval.2016.08.274
HEOR Topics :
Tags :
Regions :